Clinical and Genetic Features of Brainstem Glioma in Adults: A Report of 50 Cases in a Single Center
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background and Purpose Brainstem gliomas (BSGs) in adults are rare brain tumors with dismal outcomes. The aim of this study was to determine the clinical and genetic features in a series of BSGs and their association with the prognosis. Methods Fifty patients who underwent a stereotactic biopsy between January 2016 and April 2018 at a single institution were collected. Data on clinicopathological characteristics were analyzed and factors associated with patient survival were identified using a Cox regression model. Results The median age at diagnosis was 55.5 years, and 62% of the patients were male. Glioblastoma (44%) accounted for the largest proportion of BSGs, and oligodendroglioma (2 of 50) was rarely encountered. The IDH mutation (6 of 44) occurred infrequently in astrocytomas, and IDH-mutant tumors harbored both ATRX loss and MGMT promoter methylation at a relatively low level. Wild-type IDH astrocytomas were identified as having high rates of 1p/19q codeletion (5 of 38) and loss of heterozygosity 1p (8 of 38) or 19q (8 of 38) only. In diffuse midline glioma H3K27M mutant, MGMT promoter methylation occurred in three of four cases. Patients were offered radiotherapy and/or concurrent/adjuvant temozolomide chemotherapy, and their median survival time was 13 months. Multivariate analysis revealed that a low tumor grade, absence of tumor enhancement, duration of symptoms ≥3 months, Karnofsky performance status ≥70, and ATRX loss conferred a survival advantage. Conclusions Adult BSGs showed different molecular genetic characteristics, but also resembled supratentorial gliomas in their clinical features associated with oncological outcomes.
Abstract
Background and Purpose Brainstem gliomas (BSGs) in adults are rare brain tumors with dismal outcomes. The aim of this study was to determine the clinical and genetic features in a series of BSGs and their association with the prognosis. Methods Fifty patients who underwent a stereotactic biopsy between January 2016 and April 2018 at a single institution were collected. Data on clinicopathological characteristics were analyzed and factors associated with patient survival were identified using a Cox regression model. Results The median age at diagnosis was 55.5 years, and 62% of the patients were male. Glioblastoma (44%) accounted for the largest proportion of BSGs, and oligodendroglioma (2 of 50) was rarely encountered. The IDH mutation (6 of 44) occurred infrequently in astrocytomas, and IDH-mutant tumors harbored both ATRX loss and MGMT promoter methylation at a relatively low level. Wild-type IDH astrocytomas were identified as having high rates of 1p/19q codeletion (5 of 38) and loss of heterozygosity 1p (8 of 38) or 19q (8 of 38) only. In diffuse midline glioma H3K27M mutant, MGMT promoter methylation occurred in three of four cases. Patients were offered radiotherapy and/or concurrent/adjuvant temozolomide chemotherapy, and their median survival time was 13 months. Multivariate analysis revealed that a low tumor grade, absence of tumor enhancement, duration of symptoms ≥3 months, Karnofsky performance status ≥70, and ATRX loss conferred a survival advantage. Conclusions Adult BSGs showed different molecular genetic characteristics, but also resembled supratentorial gliomas in their clinical features associated with oncological outcomes.
참고문헌 (34)
- Ostrom QT, "CBTRUS Statistical Report : primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014", Neuro Oncol, 19, pp.v1~ (2017)
- Khalid SI, "Pediatric Brainstem gliomas : a retrospective study of 180 patients from the SEER database", Pediatr Neurosurg, 54, pp.151~164 (2019)
- Eisele SC, "Adult brainstem gliomas", Cancer, 122, pp.2799~2809 (2016)
- Guillamo JS, "Brainstem gliomas in adults : prognostic factors and classification", Brain, 124, pp.2528~2539 (2001)
- Landolfi JC, "Adult brainstem gliomas", Neurology, 51, pp.1136~1139 (1998)
- Kerezoudis P, "The role of radiation and chemotherapy in adult patients with highgrade brainstem gliomas : results from the National Cancer Database", J Neurooncol, 146, pp.303~310 (2020)
- Doyle J, "Association between extent of resection on survival in adult brainstem high-grade glioma patients", J Neurooncol, 145, pp.479~486 (2019)
- Rachinger W, "Serial stereotactic biopsy of brainstem lesions in adults improves diagnostic accuracy compared with MRI only", J Neurol Neurosurg Psychiatry, 80, pp.1134~1139 (2009)
- Hamisch C, "Update on the diagnostic value and safety of stereotactic biopsy for pediatric brainstem tumors : a systematic review and meta-analysis of 735 cases", J Neurosurg Pediatr, 20, pp.261~268 (2017)
- Molinaro AM, "Genetic and molecular epidemiology of adult diffuse glioma", Nat Rev Neurol, 15, pp.405~417 (2019)
- Yan H, "IDH1 and IDH2 mutations in gliomas", N Engl J Med, 360, pp.765~773 (2009)
- Reyes-Botero G, "Molecular analysis of diffuse intrinsic brainstem gliomas in adults", J Neurooncol, 116, pp.405~411 (2014)
- Banan R, "Infratentorial IDH-mutant astrocytoma is a distinct subtype", Acta Neuropathol, 140, pp.569~581 (2020)
- Chen L, "Predicting the likelihood of an isocitrate dehydrogenase 1 or 2 mutation in diagnoses of infiltrative glioma", Neuro Oncol, 16, pp.1478~1483 (2014)
- Reuss DE, "ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an"integrated"diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma", Acta Neuropathol, 129, pp.133~146 (2015)
- Karsy M, "New molecular considerations for glioma : IDH, ATRX, BRAF, TERT, H3 K27M", Curr Neurol Neurosci Rep, 17, pp.19~ (2017)
- Ohba S, "Correlation between IDH, ATRX, and TERT promoter mutations in glioma", Brain Tumor Pathol, 37, pp.33~40 (2020)
- Wiestler B, "ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis", Acta Neuropathol, 126, pp.443~451 (2013)
- Xie Y, "Omics-based integrated analysis identified ATRX as a biomarker associated with glioma diagnosis and prognosis", Cancer Biol Med, 16, pp.784~796 (2019)
- Fukuoka K, "Brainstem oligodendroglial tumors in children : two case reports and review of literatures", Childs Nerv Syst, 31, pp.449~455 (2015)
- Hodges SD, "Rare brainstem oligodendroglioma in an adult patient : presentation, molecular characteristics and treatment response", J Neurol Sci, 355, pp.209~210 (2015)
- Andrews C, "1p", 19q co-deleted fibrillary astrocytomas : not everything that is co-deleted is an oligodendroglioma, 2020, pp.46, 151519~
- Xiong J, "Chromosome 1p", 19q status combined with expression of p53 protein improves the diagnostic and prognostic evaluation of oligodendrogliomas, 2010, pp.123, 3566~3573
- Castel D, "Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes", Acta Neuropathol, 130, pp.815~827 (2015)
- Duchatel RJ, "Signal transduction in diffuse intrinsic pontine glioma", Proteomics, 19, pp.e1800479~ (2019)
- Feng J, "The H3. 3 K27M mutation results in a poorer prognosis in brainstem gliomas than thalamic gliomas in adults", Hum Pathol, 46, pp.1626~1632 (2015)
- Babu R, "Malignant brainstem gliomas in adults : clinicopathological characteristics and prognostic factors", J Neurooncol, 119, pp.177~185 (2014)
- Boots-Sprenger SH, "Significance of complete 1p", 19q co-deletion, IDH1 mutation and MGMT promoter methylation in gliomas : use with caution, 2013, pp.26, 922~929
- Hegi ME, "MGMT gene silencing and benefit from temozolomide in glioblastoma", N Engl J Med, 352, pp.997~1003 (2005)
- Meyronet D, "Characteristics of H3 K27M-mutant gliomas in adults", Neuro Oncol, 19, pp.1127~1134 (2017)
- Filbin MG, "Gliomas genomics and epigenomics : arriving at the start and knowing it for the first time", Annu Rev Pathol, 11, pp.497~521 (2016)
- Hu J, "Brainstem glioma in adults", Front Oncol, 6, pp.180~ (2016)
- Reithmeier T, "Retrospective analysis of 104 histologically proven adult brainstem gliomas : clinical symptoms, therapeutic approaches and prognostic factors", BMC Cancer, 14, pp.115~ (2014)
- Lapointe S, "Primary brain tumours in adults", Lancet, 392, pp.432~446 (2018)